CD274 and neoplasm: The PD-1/PD-L1 axis, with its ability to evade the anti-tumor immune response, has emerged as a prominent therapeutic target in melanoma and other malignancies [10] and expression of PD-L1 is used as a predictive biomarker of response to immunotherapy [11].